Accuray (ARAY) Set to Announce Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY – Get Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, April 27th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Shares of NASDAQ ARAY opened at $3.51 on Wednesday. The company has a quick ratio of 1.11, a current ratio of 1.72 and a debt-to-equity ratio of 3.42. The firm’s 50-day moving average price is $3.40 and its two-hundred day moving average price is $4.19. Accuray has a 52-week low of $3.10 and a 52-week high of $5.93. The stock has a market capitalization of $325.50 million, a P/E ratio of -27.00 and a beta of 1.91.

In other Accuray news, President Suzanne C. Winter purchased 11,239 shares of the business’s stock in a transaction dated Monday, January 31st. The shares were bought at an average price of $3.53 per share, with a total value of $39,673.67. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Michael Hoge sold 11,653 shares of Accuray stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $3.43, for a total value of $39,969.79. The disclosure for this sale can be found here. Insiders own 4.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. LPL Financial LLC acquired a new position in shares of Accuray during the fourth quarter valued at approximately $57,000. Royal Bank of Canada increased its stake in shares of Accuray by 171.9% during the third quarter. Royal Bank of Canada now owns 17,223 shares of the medical equipment provider’s stock valued at $68,000 after acquiring an additional 10,889 shares during the period. Jane Street Group LLC acquired a new position in shares of Accuray during the third quarter valued at approximately $69,000. Cetera Investment Advisers acquired a new position in shares of Accuray during the fourth quarter valued at approximately $72,000. Finally, Parametric Portfolio Associates LLC increased its stake in shares of Accuray by 16.3% during the fourth quarter. Parametric Portfolio Associates LLC now owns 38,951 shares of the medical equipment provider’s stock valued at $186,000 after acquiring an additional 5,465 shares during the period. Institutional investors and hedge funds own 70.43% of the company’s stock.

ARAY has been the topic of a number of recent research reports. StockNews.com began coverage on shares of Accuray in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Loop Capital began coverage on Accuray in a report on Tuesday, December 21st. They set a “buy” rating and a $7.50 price target on the stock.

About Accuray (Get Rating)

Accuray Incorporated develops, manufactures, and sells radiotherapy systems for alternative cancer treatments in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney.

Recommended Stories